Pan-EU Real-World Experience with ImraldI (PROPER)
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: BIOGEN INTERNATIONAL GMBH
- Execution start: 24/07/2020
- End of execution: 30/09/2021
- IP: RAFAEL CALIZ CALIZ
COMMERCIAL POST AUTHORIZATION STUDY